FDA begins safety review of Takeda's Actos over cancer risk
This article was originally published in Scrip
Executive Summary
The US FDA has started a safety review of Takeda's blockbuster oral antidiabetic Actos (pioglitazone) after receiving early results provided by Takeda concerning an ongoing, 10-year epidemiological study. Data from a planned, five-year analysis have suggested a possible increase in bladder cancer in patients taking the drug for more than 24 months.